

July 30, 2018 Sumitomo Dainippon Pharma Co., Ltd.

Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells

Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA), Kyoto University announced today that physician-initiated clinical trials for Parkinson's disease that transplants dopamine progenitor cells generated from induced pluripotent stem (iPS) cells are scheduled to begin on August 1, 2018.

For more information about this announcement, please refer to the press release, "Announcement of physician-initiated clinical trials for Parkinson's disease" posted on CiRA's website. (http://www.cira.kyoto-u.ac.jp/e/pressrelease/news/180730-170000.html)

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) is working toward practical use of the treatment in collaboration with CiRA.

Contact: Public & Investor Relations Group, Corporate Governance Sumitomo Dainippon Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)